My blood pressure normalization journey — July 2024

LibrarianMeg said:

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

I read this differently from LibrarianMeg, on substance rather than tone. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

JessicaH_TX said:

My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 4 of 5 diagnostic criteria to meeting ZERO after 9 months of treatment.

The 5 criteria (and my journey):

1. Waist circumference: 48" → 36" ✅ Resolved
2. Triglycerides: 274 → 119 ✅ Resolved
3. HDL: 32 → 56 ✅ Resolved
4. Blood pressure: 144/96 → 122/76 ✅ Resolved
5. Fasting glucose: 124 → 84 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

mike_nyc said:

The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -2.4 lbs/week average
Fasting glucose (finger stick): stable at 87 mg/dL
Blood pressure (home): 119/73 average
Resting heart rate: 67 bpm (down from 83)
Waist circumference: down 17 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

Following on from Dr.SleepRoch — and this may be the naive question:

What would you measure differently if you were starting again?

Dr.RaviCardio said:

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.